Despite the large body of evidence-based medical evidence showing that lipid-modifying therapy is highly beneficial in patients with hyperlipidemia, this fact is often overlooked in the middle-aged and elderly population. A Canadian study showed unsatisfactory correction of risk factors in hospitalized patients at high cardiovascular risk, with lower control rates, especially in women and the elderly. Another study showed that only 33% of the elderly population at high risk for acute myocardial infarction received lipid-modifying therapy, reflecting inadequate attention to dyslipidemia in the elderly by both physicians and patients. Elevated total serum cholesterol or low-density lipoprotein cholesterol (LDL-C) is an independent risk factor for coronary heart disease and ischemic stroke. The Guidelines for the Prevention and Treatment of Dyslipidemia in Chinese Adults states that LDL-C is the main component of cholesterol that causes atherosclerosis and is the main target of cholesterol-lowering therapy. Three major principles should be followed for lipid regulation 1. Select drugs according to the type of dyslipidemia At present, the most commonly used clinical lipid regulating drugs are statins, betablockers and niacin. Statins mainly reduce LDL-C, while beta and niacin mainly reduce triglycerides. In addition, they all have the effect of mildly increasing HDL-C. In case of severe mixed hyperlipidemia, when statins and fibrates or niacin are used in combination, it is advisable to choose drugs with less drug interactions according to their pharmacokinetic characteristics, and to start with their respective small doses and closely observe the side effects. 2. Long-term medication The course of dyslipidemia is similar to that of hypertension and requires long-term or even lifelong medication. Once the medication is stopped, most of them will return to the original level within a few weeks. Therefore, if there are no serious side effects, patients with hyperlipidemia should adhere to long-term medication. Both good lifestyle and drug therapy need to be maintained over time to achieve clinical benefit. If there are no serious adverse reactions, the dosage is usually not reduced or stopped. 3.Strengthen monitoring To ensure safety, liver function and creatine kinase should be measured before taking the medication, during the initial 4-8 weeks of taking the medication, as well as during regular rechecking of blood lipids in the future, in order to detect side effects in a timely manner. If the serum transaminase (GPT) exceeds 3 times the upper limit of normal, the drug should be suspended. Liver function impairment caused by drugs usually appears within 3 months of drug use, mostly as mild transaminase elevation, which can gradually return to normal after stopping the drug. If creatine kinase exceeds 5 times the upper limit of normal, the drug should be suspended. If serum aminotransferase is significantly elevated (2 times higher than the upper limit of normal) before taking lipid regulating drugs, you should first quit drinking, rest and liver protection treatment, and then start lipid regulating treatment after serum aminotransferase is normalized. For those whose serum aminotransferases are elevated below 2 times the upper limit of normal, lipid regulating therapy can be considered while closely monitoring liver function.